Update: New drug combination for early treatment of some metastatic prostate cancer
Summary
The FDA approved Lynparza (olaparib) for use earlier in treatment of metastatic castration-resistant prostate cancer (mCRPC) when added to abiraterone and prednisone for people with a BRCA mutation found through genetic or tumor testing. Lynparza combined with hormone therapy may now be used as a first-line or later treatment. (Posted 9/11/23)
Este artículo está disponible en español.
Printer Friendly Page Read the Original Article
RELEVANCE
Most relevant for: People with metastatic castration resistant prostate cancer with a mutation in BRCA1 or BRCA2.
It may also be relevant for:
- people with metastatic or advanced cancer
- people with a genetic mutation linked to cancer risk
- people with a family history of cancer
- people with castration-resistant prostate cancer
Relevance: Medium-High
Research Timeline: Post Approval
What is this update about?
The FDA-approved Lynparza in combination with Zytiga () and prednisone (or prednisolone) as a treatment for castration-resistant cancer for people with or mutation found on genetic testing or tumor testing.
This approval is based on the results of a large clinical trial called the PROpel trial. Prior to the study participants had received to treat mCRPC but no other hormonal agents or chemotherapy. Participants were divided into two groups. All participants received Zytiga and prednisone. Half of the participants also received Lynparza and the other half received a sugar pill ().
People who tested positive for a mutation responded especially well to Lynparza plus abiraterone compared to those who had placebo and abiraterone. After eight months, people with a BRCA1 or BRCA2 mutation who received Lynparza plus abiraterone were more likely to survive and less likely to have their cancer progress.
About Lynparza
Lynparza is a type of known as a . Like other PARP inhibitors, it can be effective against cancers with mutations in BRCA1 and BRCA2.
Lynparza () is a pill. The most common side effects, in order of frequency, are:
- Low red blood cells (anemia)
- Fatigue
- Nausea
- Diarrhea
- Decreased appetite
- Low white blood cells (Lymphopenia)
- Dizziness
- Stomach pain
In the clinical trial that led to this approval, almost 1 of 5 people taking Lynparza needed to receive at least one blood transfusion. One of 10 required more than one blood transfusion; however, they were still able to continue taking the drug.
